NaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial
DALLAS--(BUSINESS WIRE)--NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the…
4 years ago
NaturalShrimp Collaborates with Australian Companies in a Prawn Farm Wastewater Trial
DALLAS--(BUSINESS WIRE)--NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the…
4 years ago
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical…
4 years ago
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical…
4 years ago
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical…
4 years ago
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN,…
4 years ago
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN,…
4 years ago
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN,…
4 years ago
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial…
4 years ago
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial…
4 years ago